Pelvik infeksiyonlarda antibiyotik seçimi

Pelvik inflamatuvar hastalık (PİH) servisit, endometrit, salpinjit, tüboovarian apse, pelvik peritonit gibi kadınların üst genital sistem infeksiyonlarından bir veya daha fazlasını kapsayanan klinik bir sendromdur. Etiyolojik etkenler genellikle cinsel yolla bulaşan mikroorganizmalar olmakla birlikte vajinal flora üyeleri de bu infeksiyonlarla ilişkili olabilir. PİH hafif orta hastalıktan ağır hastalığa kadar değişen oldukça farklı klinik belirti ve bulgularla ortaya çıkabilir. PİH’da antimikrobiyal teda vi empirik ve muhtemel mikroorganizmalara etkili geniş spektrumlu olmalı, gonokok ve klamidyaya etkili olmalıdır. Bu yazıda PİH’lı hastaya yaklaşım ve Hastalıklar Kontrol ve Önleme Merkezi (CDC) önerilerine göre tedavi rejimleri sunulmuştur.

Antibiotic choice in pelvic ınfections

Pelvic inflamatory disease (PID) is a clinical syndrome; including one or more of upper female genital tract infections such as cervicitis, endometritis, salpingitis, tuboovarian abscess, pelvic peritonitis. Etiological agents are usually sexually transmitted microorganisms however members of vaginal flora also may be associated with those infections. PID occurs with wide variations of clinical symptoms and signs from mild-modarete to severe disease. Antimicrobial treatment in PID should be empirical and broad spectrum coverage of likely microoragnisms and should be effective against gonococci and chlamydia. In this article management of the patient with PID and empirical treatment regimens according to Centers for Disease Control and Prevention (CDC) recommendations is presented.

PDF

___

1. Balamuth F, Zhao H, Mollen C. Toward impro ving the diagnosis and the treatment of adolescent pelvic inflammatory disease in emergency depart ments: results of a brief, educational intervention, Pediatr Emerg Care 2010;26(2):85-92. http://dx.doi.org/10.1097/PEC.0b013e3181 cdf349 PMid:20094001
2. Beerthuizen RJ. Pelvic inflammatory disease in intrauterine device users, Eur J Contracept Reprod Health Care 1996;1(3):237-43. http://dx.doi.org/10.3109/13625189609150665
3. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception, Am J Obstet Gynecol 2004;190(4 Suppl):S5-22. http://dx.doi.org/10.1016/j.ajog.2004.01.061 PMid:15105794
4. Center for Disease Control and Prevention. Sexually Transmitted Disease Prevention, Ready to-Use STD Curriculum for Clinical Educators, Pelvic Inflammatory Disease (PID) Module May 2009, http://www2.cdc.gov/stdtraining/ready to-use/Manuals.
5. Center for Disease Control and Prevention. 2010 Sexually Transmitted Disease Treatment Guide lines, http://www.cdc.gov/STD/treat ment/2010.
6. Eschenbach DA (Çevirenler Çelik H, Deniz R, Yavuz A). Pelvik ve seksüel geçişli hastalıklar “Gibbs RS, Karlan BY, Haney AF, Nygaard IE (eds). (Çeviri ed. Ayhan A). Danforth’s Obstetrics and Gynecology, 10th ed” kitabının çevirisinde s.1073-85, Güneş Tıp Kitabevleri, Ankara (2010).
7. Golden MR, Whittington WL, Handsfield HH et al. Effect of expe¬dited treatment of sex partners on recurrent or persistent gonorrhea or chlamydi al infection, N Engl J Med 2005;352(7):676-85. http://dx.doi.org/10.1056/NEJMoa041681 PMid:15716561
8. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease, Infect Dis Obstet Gynecol 2011;2011:753037 (Epub 2011 Jul 26).
9. Ness RB, Soper DE, Holley RL et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Ran domized Trial, Am J Obstet Gynecol 2002;186(5): 929-37. http://dx.doi.org/10.1067/mob.2002.121625 PMid:12015517
10. Özalp S. Pelvik inflamatuvar hastalık ve tuboo varyen apse, “Topçu AW, Söyletir G, Doğanay M (eds). İnfeksiyon Hastalıkları ve Mikrobiyolojisi, Cilt 1, Üçüncü baskı” kitabında s.1509-16, Nobel Tıp Kitabevleri, İstanbul (2008).
11. Schillinger JA, Kissinger P, Calvet H et al. Patient delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infecti on among women: a randomized, controlled trial, Sex Transm Dis 2003;30(1):49-56. http://dx.doi.org/10.1097/00007435-200301000- 00011 PMid:12514443
12. Soper DE. Pelvic inflammatory disease, Obstet Gynecol 2010;116(2 Pt 1):419-28. http://dx.doi.org/10.1097/AOG.0b013e3181e 92c54
13. Sweet RL. Treatment strategies for pelvic inflam matory disease, Expert Opin Pharacother 2009;10(5): 823-37. http://dx.doi.org/10.1517/14656560902823816 PMid:19351231
14. Trent M, Haggerty CL, Jennings JM, Lee S, Bass DC, Ness R. Adverse adolescent reproductive health outcomes after pelvic inflammatory disea se, Arch Pediatr Adolesc Med 2011;165(1):49-54. http://dx.doi.org/10.1001/archpediatrics.2010. 256 PMid:21199980
15. Westrom L. Effect of acute pelvic inflamatory dise ase on fertility, Am J Obstet Gynecol 1975;121(5): 707-13. PMid:123123
16. Westrom L. Incidence, prevalence and trends of acute pelvic inflammatory disease and its conse quences in industrialized countries, Am J Obstet Gynecol 1980;138(7 Pt 2):880-92. PMid:7008604